Laboratory diagnosis of Lassa fever

Journal of Clinical Microbiology

Volumn 55, Issue 6, 2017, Pages 1629-1637

  Raabe, Vanessa ^a   Koehler, Jeffrey ^b  

^a EMORY UNIVERSITY   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

Lassa fever

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; RIBAVIRIN;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN DETECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FALSE POSITIVE RESULT; GENETIC VARIABILITY; HUMAN; IMMUNOFLUORESCENCE TEST; LASSA FEVER; MORTALITY RATE; NONHUMAN; POINT OF CARE TESTING; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; VIREMIA; VIRUS CULTURE; VIRUS INACTIVATION; VIRUS ISOLATION; AFRICA; DIAGNOSTIC TEST; ISOLATION AND PURIFICATION; LABORATORY TECHNIQUE; LASSA VIRUS; PROCEDURES;

AFRICA, WESTERN; CLINICAL LABORATORY TECHNIQUES; DIAGNOSTIC TESTS, ROUTINE; HUMANS; LASSA FEVER; LASSA VIRUS;

EID: 85019574395     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00170-17     Document Type: Short Survey

References (67)

1. Buckley SM, Casals J. 1970. Lassa fever, a new virus disease of man from West Africa. 3. Isolation and characterization of the virus. Am J Trop Med Hyg 19:680-691.
2. McCormick JB, Webb PA, Krebs JW, Johnson KM, Smith ES. 1987. A prospective study of the epidemiology and ecology of Lassa fever. J Infect Dis 155:437-444. https://doi.org/10.1093/infdis/155.3.437.
3. Centers for Disease Control and Prevention. Lassa fever. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/vhf/lassa/pdf/factsheet.pdf. Accessed 2 November 2016.
4. McCormick JB, King IJ, Webb PA, Johnson KM, O'Sullivan R, Smith ES, Trippel S, Tong TC. 1987. A case-control study of the clinical diagnosis and course of Lassa fever. J Infect Dis 155:445-455. https://doi.org/10.1093/infdis/155.3.445.
5. National Institute of Allergy and Infectious Diseases. 26 October 2016. NIAID emerging infectious diseases/pathogens. National Institute of Allergy and Infectious Diseases, Bethesda, MD. https://www.niaid.nih.gov/research/emerging-infectious-diseases-pathogens. Accessed 29 October 2016.
6. Centers for Disease Control and Prevention. 1988. Management of patients with suspected viral hemorrhagic fever. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/MMWR/preview/mmwrhtml/00037085.htm.
7. World Health Organization. 2016. WHO calls for early diagnostic tests for Lassa fever. World Health Organization, Geneva, Switzerland. http://www.who.int/csr/disease/lassafever/early-diagnostic-lassa-fever/en/. Accessed 20 October 2016.
8. World Health Organization. March 2016. Lassa fever. World Health Organization, Geneva, Switzerland. http://www.who.int/mediacentre/factsheets/fs179/en/. Accessed 20 October 2016.
9. Frame JD, Baldwin JM, Jr, Gocke DJ, Troup JM. 1970. Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings. Am J Trop Med Hyg 19:670-676.
10. Richmond JK, Baglole DJ. 2003. Lassa fever: epidemiology, clinical features, and social consequences. BMJ 327:1271-1275. https://doi.org/10.1136/bmj.327.7426.1271.
11. McCormick JB, Walker DH, King IJ, Webb PA, Elliott LH, Whitfield SG, Johnson KM. 1986. Lassa virus hepatitis: a study of fatal Lassa fever in humans. Am J Trop Med Hyg 35:401-407.
12. Price ME, Fisher-Hoch SP, Craven RB, McCormick JB. 1988. A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy. BMJ 297:584-587. https://doi.org/10.1136/bmj.297.6648.584.
13. McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM, Elliott LH, Belmont-Williams R. 1986. Lassa fever. Effective therapy with ribavirin. N Engl J Med 314:20-26. https://doi.org/10.1056/NEJM198601023140104.
14. O'Hearn AE, Voorhees MA, Fetterer DP, Wauquier N, Coomber MR, Bangura J, Fair JN, Gonzalez JP, Schoepp RJ. 2016. Serosurveillance of viral pathogens circulating in West Africa. Virol J 13:163. https://doi.org/10.1186/s12985-016-0621-4.
15. Schoepp RJ, Rossi CA, Khan SH, Goba A, Fair JN. 2014. Undiagnosed acute viral febrile illnesses, Sierra Leone. Emerg Infect Dis 20:1176-1182. https://doi.org/10.3201/eid2007.131265.
16. World Health Organization. 2014. Interim guideline: laboratory diagnosis of Ebola virus disease. World Health Organization, Geneva, Switzerland.
17. World Health Organization. 2014. Interim guidance: how to safely ship human blood samples from suspected Ebola cases within a country by road, rail and sea. World Health Organization, Geneva, Switzerland.
18. World Health Organization. 2014. How to safely collect blood samples by phlebotomy from patients suspected to be infected with Ebola. World Health Organization, Geneva, Switzerland.
19. Pan American Health Organization, World Health Organization. 2015. General procedures for inactivation of potentially infectious samples with Ebola virus and other highly pathogenic viral agents. Regional Office for the Americas of the World Health Organization, Washington, DC.
20. Blow JA, Dohm DJ, Negley DL, Mores CN. 2004. Virus inactivation by nucleic acid extraction reagents. J Virol Methods 119:195-198. https://doi.org/10.1016/j.jviromet.2004.03.015.
21. Haddock E, Feldmann F, Feldmann H. 2016. Effective chemical inactivation of Ebola virus. Emerg Infect Dis 22:1292-1294. https://doi.org/10.3201/eid2207.160233.
22. Smither SJ, Weller SA, Phelps A, Eastaugh L, Ngugi S, O'Brien LM, Steward J, Lonsdale SG, Lever MS. 2015. Buffer AVL alone does not inactivate Ebola virus in a representative clinical sample type. J Clin Microbiol 53:3148-3154. https://doi.org/10.1128/JCM.01449-15.
23. Mitchell SW, McCormick JB. 1984. Physicochemical inactivation of Lassa, Ebola, and Marburg viruses and effect on clinical laboratory analyses. J Clin Microbiol 20:486-489.
24. King AMQ, Lefkowitz E, Adams MJ, Carstens EB (ed). 2012. Family - Arenaviridae, p 715-723, Virus taxonomy. Ninth report of the International Committee on Taxonomy of Viruses. Elsevier, Philadelphia, PA.
25. Elliott LH, McCormick JB, Johnson KM. 1982. Inactivation of Lassa, Marburg, and Ebola viruses by gamma irradiation. J Clin Microbiol 16:704-708.
26. Sagripanti JL, Lytle CD. 2011. Sensitivity to ultraviolet radiation of Lassa, vaccinia, and Ebola viruses dried on surfaces. Arch Virol 156:489-494. https://doi.org/10.1007/s00705-010-0847-1.
27. Lytle CD, Sagripanti JL. 2005. Predicted inactivation of viruses of relevance to biodefense by solar radiation. J Virol 79:14244-14252. https://doi.org/10.1128/JVI.79.22.14244-14252.2005.
28. Demby AH, Chamberlain J, Brown DW, Clegg CS. 1994. Early diagnosis of Lassa fever by reverse transcription-PCR. J Clin Microbiol 32:2898-2903.
29. Olschlager S, Lelke M, Emmerich P, Panning M, Drosten C, Hass M, Asogun D, Ehichioya D, Omilabu S, Gunther S. 2010. Improved detection of Lassa virus by reverse transcription-PCR targeting the 5′ region of S RNA. J Clin Microbiol 48:2009-2013. https://doi.org/10.1128/JCM.02351-09.
30. NCBI Resource Coordinators. 2016. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 44:D7-D19. https://doi.org/10.1093/nar/gkv1290.
31. Emmerich P, Gunther S, Schmitz H. 2008. Strain-specific antibody response to Lassa virus in the local population of West Africa. J Clin Virol 42:40-44. https://doi.org/10.1016/j.jcv.2007.11.019.
32. Lukashevich IS, Carrion R, Jr, Salvato MS, Mansfield K, Brasky K, Zapata J, Cairo C, Goicochea M, Hoosien GE, Ticer A, Bryant J, Davis H, Hammamieh R, Mayda M, Jett M, Patterson J. 2008. Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine 26:5246-5254. https://doi.org/10.1016/j.vaccine.2008.07.057.
33. Carrion R, Jr, Patterson JL, Johnson C, Gonzales M, Moreira CR, Ticer A, Brasky K, Hubbard GB, Moshkoff D, Zapata J, Salvato MS, Lukashevich IS. 2007. A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity. Vaccine 25:4093-4102. https://doi.org/10.1016/j.vaccine.2007.02.038.
34. Bowen MD, Rollin PE, Ksiazek TG, Hustad HL, Bausch DG, Demby AH, Bajani MD, Peters CJ, Nichol ST. 2000. Genetic diversity among Lassa virus strains. J Virol 74:6992-7004. https://doi.org/10.1128/JVI.74.15.6992-7004.2000.
35. Johnson KM, McCormick JB, Webb PA, Smith ES, Elliott LH, King IJ. 1987. Clinical virology of Lassa fever in hospitalized patients. J Infect Dis 155:456-464. https://doi.org/10.1093/infdis/155.3.456.
36. Bausch DG, Rollin PE, Demby AH, Coulibaly M, Kanu J, Conteh AS, Wagoner KD, McMullan LK, Bowen MD, Peters CJ, Ksiazek TG. 2000. Diagnosis and clinical virology of Lassa fever as evaluated by enzyme-linked immunosorbent assay, indirect fluorescent-antibody test, and virus isolation. J Clin Microbiol 38:2670-2677.
37. Drosten C, Kummerer BM, Schmitz H, Gunther S. 2003. Molecular diagnostics of viral hemorrhagic fevers. Antiviral Res 57:61-87. https://doi.org/10.1016/S0166-3542(02)00201-2.
38. Gunther S, Weisner B, Roth A, Grewing T, Asper M, Drosten C, Emmerich P, Petersen J, Wilczek M, Schmitz H. 2001. Lassa fever encephalopathy: Lassa virus in cerebrospinal fluid but not in serum. J Infect Dis 184:345-349. https://doi.org/10.1086/322033.
39. Monath TP, Casals J. 1975. Diagnosis of Lassa fever and the isolation and management of patients. Bull World Health Organ 52:707-715.
40. Trappier SG, Conaty AL, Farrar BB, Auperin DD, McCormick JB, Fisher-Hoch SP. 1993. Evaluation of the polymerase chain reaction for diagnosis of Lassa virus infection. Am J Trop Med Hyg 49:214-221.
41. Drosten C, Gottig S, Schilling S, Asper M, Panning M, Schmitz H, Gunther S. 2002. Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. J Clin Microbiol 40:2323-2330. https://doi.org/10.1128/JCM.40.7.2323-2330.2002.
42. Vieth S, Drosten C, Lenz O, Vincent M, Omilabu S, Hass M, Becker-Ziaja B, ter Meulen J, Nichol ST, Schmitz H, Gunther S. 2007. RT-PCR assay for detection of Lassa virus and related Old World arenaviruses targeting the L gene. Trans R Soc Trop Med Hyg 101:1253-1264. https://doi.org/10.1016/j.trstmh.2005.03.018.
43. Stadhouders R, Pas SD, Anber J, Voermans J, Mes TH, Schutten M. 2010. The effect of primer-template mismatches on the detection and quantification of nucleic acids using the 5′ nuclease assay. J Mol Diagn 12:109-117. https://doi.org/10.2353/jmoldx.2010.090035.
44. Trombley AR, Wachter L, Garrison J, Buckley-Beason VA, Jahrling J, Hensley LE, Schoepp RJ, Norwood DA, Goba A, Fair JN, Kulesh DA. 2010. Comprehensive panel of real-time TaqMan polymerase chain reaction assays for detection and absolute quantification of filoviruses, arenaviruses, and New World hantaviruses. Am J Trop Med Hyg 82:954-960. https://doi.org/10.4269/ajtmh.2010.09-0636.
45. Safronetz D, Lopez JE, Sogoba N, Traore SF, Raffel SJ, Fischer ER, Ebihara H, Branco L, Garry RF, Schwan TG, Feldmann H. 2010. Detection of Lassa virus, Mali. Emerg Infect Dis 16:1123-1126. https://doi.org/10.3201/eid1607.100146.
46. Nikisins S, Rieger T, Patel P, Muller R, Gunther S, Niedrig M. 2015. International external quality assessment study for molecular detection of Lassa virus. PLoS Negl Trop Dis 9:e0003793. https://doi.org/10.1371/journal.pntd.0003793.
47. Pang Z, Li A, Li J, Qu J, He C, Zhang S, Li C, Zhang Q, Liang M, Li D. 2014. Comprehensive multiplex one-step real-time TaqMan qRT-PCR assays for detection and quantification of hemorrhagic fever viruses. PLoS One 9:e95635. https://doi.org/10.1371/journal.pone.0095635.
48. Das S, Rundell MS, Mirza AH, Pingle MR, Shigyo K, Garrison AR, Paragas J, Smith SK, Olson VA, Larone DH, Spitzer ED, Barany F, Golightly LM. 2015. A multiplex PCR/LDR assay for the simultaneous identification of category A infectious pathogens: agents of viral hemorrhagic fever and variola virus. PLoS One 10:e0138484. https://doi.org/10.1371/journal.pone.0138484.
49. He J, Kraft AJ, Fan J, Van Dyke M, Wang L, Bose ME, Khanna M, Metallo JA, Henrickson KJ. 2009. Simultaneous detection of CDC category "A" DNA and RNA bioterrorism agents by use of multiplex PCR & RT-PCR enzyme hybridization assays. Viruses 1:441-459. https://doi.org/10.3390/v1030441.
50. Branco LM, Grove JN, Boisen ML, Shaffer JG, Goba A, Fullah M, Momoh M, Grant DS, Garry RF. 2011. Emerging trends in Lassa fever: redefining the role of immunoglobulin M and inflammation in diagnosing acute infection. Virol J 8:478. https://doi.org/10.1186/1743-422X-8-478.
51. Jahrling PB, Niklasson BS, McCormick JB. 1985. Early diagnosis of human Lassa fever by ELISA detection of antigen and antibody. Lancet i:250-252.
52. Bausch DG, Demby AH, Coulibaly M, Kanu J, Goba A, Bah A, Conde N, Wurtzel HL, Cavallaro KF, Lloyd E, Baldet FB, Cisse SD, Fofona D, Savane IK, Tolno RT, Mahy B, Wagoner KD, Ksiazek TG, Peters CJ, Rollin PE. 2001. Lassa fever in Guinea: I. Epidemiology of human disease and clinical observations. Vector Borne Zoonotic Dis 1:269-281. https://doi.org/10.1089/15303660160025903.
53. Satterly NG, Voorhees MA, Ames AD, Schoepp RJ. 2017. Comparison of MagPix assays and enzyme-linked immunosorbent assay for the detection of hemorrhagic fever viruses. J Clin Microbiol 55:68-78. https://doi.org/10.1128/JCM.01693-16.
54. Emmerich P, Thome-Bolduan C, Drosten C, Gunther S, Ban E, Sawinsky I, Schmitz H. 2006. Reverse ELISA for IgG and IgM antibodies to detect Lassa virus infections in Africa. J Clin Virol 37:277-281. https://doi.org/10.1016/j.jcv.2006.08.015.
55. Lukashevich IS, Clegg JC, Sidibe K. 1993. Lassa virus activity in Guinea: distribution of human antiviral antibody defined using enzyme-linked immunosorbent assay with recombinant antigen. J Med Virol 40:210-217. https://doi.org/10.1002/jmv.1890400308.
56. Saijo M, Georges-Courbot MC, Marianneau P, Romanowski V, Fukushi S, Mizutani T, Georges AJ, Kurata T, Kurane I, Morikawa S. 2007. Development of recombinant nucleoprotein-based diagnostic systems for Lassa fever. Clin Vaccine Immunol 14:1182-1189. https://doi.org/10.1128/CVI.00101-07.
57. Grove JN, Branco LM, Boisen ML, Muncy IJ, Henderson LA, Schieffellin JS, Robinson JE, Bangura JJ, Fonnie M, Schoepp RJ, Hensley LE, Seisay A, Fair JN, Garry RF. 2011. Capacity building permitting comprehensive monitoring of a severe case of Lassa hemorrhagic fever in Sierra Leone with a positive outcome: case report. Virol J 8:314. https://doi.org/10.1186/1743-422X-8-314.
58. Corgenix, Inc. 2015. ReLASV antigen rapid test package insert-IVD. Corgenix, Inc., St. Ingbert, Germany.
59. Shaffer JG, Grant DS, Schieffelin JS, Boisen ML, Goba A, Hartnett JN, Levy DC, Yenni RE, Moses LM, Fullah M, Momoh M, Fonnie M, Fonnie R, Kanneh L, Koroma VJ, Kargbo K, Ottomassathien D, Muncy IJ, Jones AB, Illick MM, Kulakosky PC, Haislip AM, Bishop CM, Elliot DH, Brown BL, Zhu H, Hastie KM, Andersen KG, Gire SK, Tabrizi S, Tariyal R, Stremlau M, Matschiner A, Sampey DB, Spence JS, Cross RW, Geisbert JB, Folarin OA, Happi CT, Pitts KR, Geske FJ, Geisbert TW, Saphire EO, Robinson JE, Wilson RB, Sabeti PC, Henderson LA, Khan SH, Bausch DG, Branco LM, Garry RF, Viral Hemorrhagic Fever Consortium. 2014. Lassa fever in post-conflict Sierra Leone. PLoS Negl Trop Dis 8:e2748. https://doi.org/10.1371/journal.pntd.0002748.
60. Wulff H, Johnson KM. 1979. Immunoglobulin M and G responses measured by immunofluorescence in patients with Lassa or Marburg virus infections. Bull World Health Organ 57:631-635.
61. Ibekwe TS, Nwegbu MM, Asogun D, Adomeh DI, Okokhere PO. 2012. The sensitivity and specificity of Lassa virus IgM by ELISA as screening tool at early phase of Lassa fever infection. Niger Med J 53:196-199. https://doi.org/10.4103/0300-1652.107552.
62. Ter Meulen J, Koulemou K, Wittekindt T, Windisch K, Strigl S, Conde S, Schmitz H. 1998. Detection of Lassa virus antinucleoprotein immunoglobulin G (IgG) and IgM antibodies by a simple recombinant immunoblot assay for field use. J Clin Microbiol 36:3143-3148.
63. Wulff H, Lange JV. 1975. Indirect immunofluorescence for the diagnosis of Lassa fever infection. Bull World Health Organ 52:429-436.
64. Bond N, Schieffelin JS, Moses LM, Bennett AJ, Bausch DG. 2013. A historical look at the first reported cases of Lassa fever: IgG antibodies 40 years after acute infection. Am J Trop Med Hyg 88:241-244. https://doi.org/10.4269/ajtmh.12-0466.
65. Fukushi S, Tani H, Yoshikawa T, Saijo M, Morikawa S. 2012. Serological assays based on recombinant viral proteins for the diagnosis of arenavirus hemorrhagic fevers. Viruses 4:2097-2114. https://doi.org/10.3390/v4102097.
66. Kerneis S, Koivogui L, Magassouba N, Koulemou K, Lewis R, Aplogan A, Grais RF, Guerin PJ, Fichet-Calvet E. 2009. Prevalence and risk factors of Lassa seropositivity in inhabitants of the forest region of Guinea: a cross-sectional study. PLoS Negl Trop Dis 3:e548. https://doi.org/10.1371/journal.pntd.0000548.
67. Olschlager S, Gunther S. 2012. Rapid and specific detection of Lassa virus by reverse transcription-PCR coupled with oligonucleotide array hybridization. J Clin Microbiol 50:2496-2499. https://doi.org/10.1128/JCM.00998-12.